Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tim Skern is active.

Publication


Featured researches published by Tim Skern.


Journal of Virology | 2008

Differential Targeting of Nuclear Pore Complex Proteins in Poliovirus-Infected Cells

Nogi Park; Pavan Katikaneni; Tim Skern; Kurt E. Gustin

ABSTRACT Poliovirus disrupts nucleocytoplasmic trafficking and results in the cleavage of two nuclear pore complex (NPC) proteins, Nup153 and Nup62. The NPC is a 125-MDa complex composed of multiple copies of 30 different proteins. Here we have extended the analysis of the NPC in infected cells by examining the status of Nup98, an interferon-induced NPC protein with a major role in mRNA export. Our results indicate that Nup98 is targeted for cleavage after infection but that this occurs much more rapidly than it does for Nup153 and Nup62. In addition, we find that cleavage of these NPC proteins displays differential sensitivity to the viral RNA synthesis inhibitor guanidine hydrochloride. Inhibition of nuclear import and relocalization of host nuclear proteins to the cytoplasm were only apparent at later times after infection when all three nucleoporins (Nups) were cleaved. Surprisingly, analysis of the distribution of mRNA in infected cells revealed that proteolysis of Nup98 did not result in an inhibition of mRNA export. Cleavage of Nup98 could be reconstituted by the addition of purified rhinovirus type 2 2Apro to whole-cell lysates prepared from uninfected cells, suggesting that the 2A protease has a role in this process in vivo. These results indicate that poliovirus differentially targets subsets of NPC proteins at early and late times postinfection. In addition, targeting of interferon-inducible NPC proteins, such as Nup98, may be an additional weapon in the arsenal of poliovirus and perhaps other picornaviruses to overcome host defense mechanisms.


Journal of Biological Chemistry | 2010

Specific cleavage of the nuclear pore complex protein Nup62 by a viral protease.

Nogi Park; Tim Skern; Kurt E. Gustin

Previous work has shown that several nucleoporins, including Nup62 are degraded in cells infected with human rhinovirus (HRV) and poliovirus (PV) and that this contributes to the disruption of certain nuclear transport pathways. In this study, the mechanisms underlying proteolysis of Nup62 have been investigated. Analysis of Nup62 in lysates from HRV-infected cells revealed that Nup62 was cleaved at multiple sites during viral infection. The addition of purified HRV2 2A protease (2Apro) to uninfected HeLa whole cell lysates resulted in the cleavage of Nup62, suggesting that 2Apro is a major contributor to Nup62 processing. The ability of purified 2Apro to cleave bacterially expressed and purified Nup62 demonstrated that 2Apro directly cleaves Nup62 in vitro. Site-directed mutagenesis of putative cleavage sites in Nup62 identified six different positions that are cleaved by 2Apro in vitro. This analysis revealed that 2Apro cleavage sites were located between amino acids 103 and 298 in Nup62 and suggested that the N-terminal FG-rich region of Nup62 was released from the nuclear pore complex in infected cells. Analysis of HRV- and PV-infected cells using domain-specific antibodies confirmed that this was indeed the case. These results are consistent with a model whereby PV and HRV disrupt nucleo-cytoplasmic trafficking by selectively removing FG repeat domains from a subset of nuclear pore complex proteins.


Archives of Virology | 2010

A proposal to change existing virus species names to non-Latinized binomials

Marc H.V. Van Regenmortel; Donald S. Burke; Charles H. Calisher; Ralf G. Dietzgen; Claude M. Fauquet; Said A. Ghabrial; Peter B. Jahrling; Karl M. Johnson; Marian C. Horzinek; Guenther M. Keil; Jens H. Kuhn; Brian W. J. Mahy; G. P. Martelli; Craig R. Pringle; Edward P. Rybicki; Tim Skern; Robert B. Tesh; Victoria Wahl-Jensen; Peter J. Walker; Scott C. Weaver

A proposal has been posted on the ICTV website (2011.001aG.N.v1.binomial_sp_names) to replace virus species names by non-Latinized binomial names consisting of the current italicized species name with the terminal word “virus” replaced by the italicized and non-capitalized genus name to which the species belongs. If implemented, the current italicized species name Measles virus, for instance, would become Measles morbillivirus while the current virus name measles virus and its abbreviation MeV would remain unchanged. The rationale for the proposed change is presented.


PLOS ONE | 2012

Translation Directed by Hepatitis A Virus IRES in the Absence of Active eIF4F Complex and eIF2

Natalia Redondo; Miguel Angel Sanz; Jutta Steinberger; Tim Skern; Yuri Kusov; Luis Carrasco

Translation directed by several picornavirus IRES elements can usually take place after cleavage of eIF4G by picornavirus proteases 2Apro or Lpro. The hepatitis A virus (HAV) IRES is thought to be an exception to this rule because it requires intact eIF4F complex for translation. In line with previous results we report that poliovirus (PV) 2Apro strongly blocks protein synthesis directed by HAV IRES. However, in contrast to previous findings we now demonstrate that eIF4G cleavage by foot-and-mouth disease virus (FMDV) Lpro strongly stimulates HAV IRES-driven translation. Thus, this is the first observation that 2Apro and Lpro exhibit opposite effects to what was previously thought to be the case in HAV IRES. This effect has been observed both in hamster BHK and human hepatoma Huh7 cells. In addition, this stimulation of translation is also observed in cell free systems after addition of purified Lpro. Notably, in presence of this FMDV protease, translation directed by HAV IRES takes place when eIF2α has been inactivated by phosphorylation. Our present findings clearly demonstrate that protein synthesis directed by HAV IRES can occur when eIF4G has been cleaved and after inactivation of eIF2. Therefore, translation directed by HAV IRES without intact eIF4G and active eIF2 is similar to that observed with other picornavirus IRESs.


Journal of General Virology | 2017

ICTV Virus Taxonomy Profile: Picornaviridae

Roland Zell; Eric Delwart; Alexander E. Gorbalenya; Tapani Hovi; Andrew M. Q. King; Nick J. Knowles; A. M. Lindberg; Mark A. Pallansch; Ann C. Palmenberg; Gábor Reuter; Peter Simmonds; Tim Skern; Glyn Stanway; T. Yamashita

The family Picornaviridae comprises small non-enveloped viruses with RNA genomes of 6.7 to 10.1 kb, and contains >30 genera and >75 species. Most of the known picornaviruses infect mammals and birds, but some have also been detected in reptiles, amphibians and fish. Many picornaviruses are important human and veterinary pathogens and may cause diseases of the central nervous system, heart, liver, skin, gastrointestinal tract or upper respiratory tract. Most picornaviruses are transmitted by the faecal–oral or respiratory routes. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on the taxonomy of the Picornaviridae, which is available at www.ictv.global/report/picornaviridae.


Archives of Virology | 2013

Virus species polemics : 14 senior virologists oppose a proposed change to the ICTV definition of virus species

Marc H.V. Van Regenmortel; Hans Wolfgang Ackermann; Charles H. Calisher; Ralf G. Dietzgen; Marian C. Horzinek; Günther M. Keil; Brian W. J. Mahy; G. P. Martelli; Frederick A. Murphy; Craig R. Pringle; B. K. Rima; Tim Skern; Heinrich-Josef Vetten; Scott C. Weaver

The Executive Committee of the International Committee on Taxonomy of Viruses (ICTV) has recently decided to modify the current definition of virus species (Code of Virus Classification and Nomenclature Rule 3.21) and will soon ask the full ICTV membership (189 voting members) to ratify the proposed controversial change. In this discussion paper, 14 senior virologists, including six Life members of the ICTV, compare the present and proposed new definition and recommend that the existing definition of virus species should be retained. Since the pros and cons of the proposal posted on the ICTV website are not widely consulted, the arguments are summarized here in order to reach a wider audience.


Journal of Biological Chemistry | 2014

Characterization and Structure of the Vaccinia Virus NF-κB Antagonist A46

Sofiya Fedosyuk; Irina Grishkovskaya; Euripedes de Almeida Ribeiro; Tim Skern

Background: Vaccinia virus encodes several anti-inflammatory proteins that interfere with host signaling pathways. Results: The protein A46 has a similar fold to other vaccinia virus anti-inflammatory proteins but uses a different dimer interface. Conclusion: Variations in quaternary structure can affect the specificity of interactions of anti-inflammatory proteins. Significance: The structure illustrates how viruses can generate versatility of function from the same protein fold. Successful vaccinia virus (VACV) replication in the host requires expression of viral proteins that interfere with host immunity, such as antagonists of the activation of the proinflammatory transcription factor NF-κB. Two such VACV proteins are A46 and A52. A46 interacts with the Toll-like receptor/interleukin-1R (TIR) domain of Toll-like receptors and intracellular adaptors such as MAL (MyD88 adapter-like), TRAM (TIR domain-containing adapter-inducing interferon-β (TRIF)-related adaptor molecule), TRIF, and MyD88, whereas A52 binds to the downstream signaling components TRAF6 and IRAK2. Here, we characterize A46 biochemically, determine by microscale thermophoresis binding constants for the interaction of A46 with the TIR domains of MyD88 and MAL, and present the 2.0 Å resolution crystal structure of A46 residues 87–229. Full-length A46 behaves as a tetramer; variants lacking the N-terminal 80 residues are dimeric. Nevertheless, both bind to the Toll-like receptor domains of MAL and MyD88 with KD values in the low μm range. Like A52, A46 also shows a Bcl-2-like fold but with biologically relevant differences from that of A52. Thus, A46 uses helices α4 and α6 to dimerize, compared with the α1-α6 face used by A52 and other Bcl-2 like VACV proteins. Furthermore, the loop between A46 helices α4-α5 is flexible and shorter than in A52; there is also evidence for an intramolecular disulfide bridge between consecutive cysteine residues. We used molecular docking to propose how A46 interacts with the BB loop of the TRAM TIR domain. Comparisons of A46 and A52 exemplify how subtle changes in viral proteins with the same fold lead to crucial differences in biological activity.


FEBS Letters | 2006

Defining residues involved in human rhinovirus 2A proteinase substrate recognition.

Carla Sousa; Eva M. Schmid; Tim Skern

The 2A proteinase (2Apro) of human rhinoviruses (HRVs) initiates proteolytic processing by cleaving between the C‐terminus of VP1 and its own N‐terminus. It subsequently cleaves the host protein eIF4GI. HRV2 and HRV14 2Apro cleave at IITTA ∗ GPSD and DIKSY ∗ GLGP on their respective polyproteins. The HRV2 2Apro cleavage site on eIF4GI is TLSTR ∗ GPPR. We show that HRV2 2Apro can self‐process at the eIF4GI cleavage sequence whereas HRV14 2Apro cannot, due to the presence of the arginine residue at P1. The mutations A104C or A104S in HRV14 2Apro restored cleavage when arginine was present at P1, although not to wild‐type levels. These experiments define residues which determine substrate recognition in rhinoviral 2Apro.


FEBS Journal | 2005

The binding of foot-and-mouth disease virus leader proteinase to eIF4GI involves conserved ionic interactions.

Nicole Foeger; Elisabeth Kuehnel; Regina Cencic; Tim Skern

The leader proteinase (Lpro) of foot‐and‐mouth disease virus (FMDV) initially cleaves itself from the polyprotein. Subsequently, Lpro cleaves the host proteins eukaryotic initiation factor (eIF) 4GI and 4GII. This prevents protein synthesis from capped cellular mRNAs; the viral RNA is still translated, initiating from an internal ribosome entry site. Lpro cleaves eIF4GI between residues G674 and R675. We showed previously, however, that Lpro binds to residues 640–669 of eIF4GI. Binding was substantially improved when the eIF4GI fragment contained the eIF4E binding site and eIF4E was present in the binding assay. Lpro interacts with eIF4GI via residue C133 and residues 183–195 of the C‐terminal extension. This binding domain lies about 25 Å from the active site. Here, we examined the binding of Lpro to eIF4GI fragments generated by in vitro translation to narrow the binding site down to residues 645–657 of human eIF4GI. Comparison of these amino acids with those in human eIF4GII as well as with sequences of eIF4GI from other organisms allowed us to identify two conserved basic residues (K646 and R650). Mutation of these residues was severely detrimental to Lpro binding. Similarly, comparison of the sequence between residues 183 and 195 of Lpro with those of other FMDV serotypes and equine rhinitis A virus showed that acidic residues D184 and E186 were highly conserved. Substitution of these residues in Lpro significantly reduced eIF4GI binding and cleavage without affecting self‐processing. Thus, FMDV Lpro has evolved a domain that specifically recognizes a host cell protein.


Biological Chemistry | 2014

The leader proteinase of foot-and-mouth disease virus: structure-function relationships in a proteolytic virulence factor.

Jutta Steinberger; Tim Skern

Abstract The leader proteinase (Lpro) of the foot-and-mouth disease virus inhibits the host innate immune response by at least three different mechanisms. The most well-characterised of these is the prevention of the synthesis of cytokines such as interferons immediately after infection, brought about by specific proteolytic cleavage of the eukaryotic initiation factor 4G. This prevents the recruitment of capped cellular mRNA; however, the viral RNA can be translated under these conditions. The two other mechanisms are the induction of NF-κB cleavage and the deubiquitination of immune signalling molecules. This review focuses on the structure-function relationships in Lpro responsible for these widely divergent activities.

Collaboration


Dive into the Tim Skern's collaboration.

Top Co-Authors

Avatar

Jutta Steinberger

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Martina Aumayr

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Georg Kontaxis

Max F. Perutz Laboratories

View shared research outputs
Top Co-Authors

Avatar

Regina Cencic

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Sofiya Fedosyuk

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Luiz Juliano

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Maria A. Juliano

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

David Neubauer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martina Kurz

Medical University of Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge